

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
23 February 2023 (23.02.2023)



(10) International Publication Number
WO 2023/023354 A3

(51) International Patent Classification:

C07K 16/28 (2006.01) A61K 39/00 (2006.01)

C07K 16/30 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2022/040931

(22) International Filing Date:

19 August 2022 (19.08.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/235,093 19 August 2021 (19.08.2021) US

(71) Applicant: ADICET THERAPEUTICS, INC. [US/US];
1000 Bridge Pkwy, Redwood City, CA 94065 (US).

(72) Inventors: HAYES, Sandra, M.; 600 Fordham Road,
San Mateo, CA 94402 (US). WONG, Jonathan, Ta
Shin; 131 Felton Street, San Francisco, CA 94134 (US).
BHAT, Arun; 11050 Durland Ave. NE, Seattle, WA 98125
(US). TURKOZ, Mustafa; 813 Salt Ct., Redwood City,
CA 94065 (US). MEADDOUGH, Erika, L.; 9771 Hopi
Lane, Gilroy, CA 95020 (US). SHAO, Hui; 211 Seville
Way, San Mateo, CA 94402 (US). WILDE, Jacqueline,
Kennedy; 1239 Mandarin Drive, Sunnyvale, CA 94087
(US). MALLER, Ori; 665 Sliver Avenue, Half Moon Bay,
CA 94019 (US). PEREZ, Elizabeth, Maoura; 191 East El
Camino Real, Space 292, Mountain View, CA 94040 (US).
HOOPES, Matthew, Ian; 1515 Timber Hills Road, Mount
Shasta, CA 96067 (US). NISHIMOTO, Kevin; 92 Valley
View Court, San Mateo, CA 94402 (US).

(74) Agent: LORENZ, Todd et al.; Squire Patton Boggs, 475
Sansome Street, 16th Floor, San Francisco, CA 94111 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(88) Date of publication of the international search report:

30 March 2023 (30.03.2023)

(54) Title: METHODS FOR DETECTION OF MEMBRANE BOUND GLYPICAN-3

(57) Abstract: Embodiments provide for anti-GPC3 antibodies compositions comprising the same, and methods of using such antibodies and compositions for the prevention, diagnosis, and treatment of cancer. In one embodiment, a method for predicting a therapeutic effect of an anti-GPC3 immunotherapy on a cancer characterized in that cells of the cancer express GPC3, comprises detecting the presence of said cells in a subject via an immunohistochemical methodology, and wherein when the presence of said cells is detected, the anti-GPC3 immunotherapy is predicted to have a therapeutic effect on the cancer in the subject.



WO 2023/023354 A3